The Pharma Data

JANUARY 6, 2021

a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. ImaginAb will receive license fees and payments for manufacturing and other support. LOS ANGELES , Jan. 7, 2021 /PRNewswire/ — ImaginAb Inc. , No other terms were disclosed.

Licensing 52

Licensing Licensing Clinical Trials Pharmaceutical Companies 52

Drug Target Review

SEPTEMBER 5, 2024

This was very challenging for me and at that moment I decided to get experience from later stage products and therefore took on the role as Global Product Director for late-stage marketed cardiovascular products. I experienced challenges in cultural differences working with US, UK, Japan, and China.

Pharma Companies 111

Pharma Companies Licensing Licensing Disease 111

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Licensing 52

Licensing Licensing Therapies Engineering 52

ASPET

OCTOBER 12, 2023

The Countering Emerging Threats - Rapid Acquisition and Investigation of Drugs for Repurposing (CET RAIDR) program within the JPM Medical is designed to rapidly tackle known, unknown, and emerging threats by utilizing late-stage or licensed therapeutics. Repurposing is one such method. CBRN MCMs).

Therapies 100

Therapies Licensing Licensing FDA Approval 100

SCIENMAG: Medicine & Health

JUNE 9, 2023

Virginia Tech Intellectual Properties (VTIP) with LINK + LICENSE + LAUNCH’s Proof-of-Concept Program has provided the springboard for faculty to bring their research to market. Over the past four years, the program has funded 24 Virginia Tech research projects. Credit: Photo by Luke Hayes for Virginia Tech.

Research 84

Research Licensing Licensing Marketing 84

BioPharma Drive: Drug Pricing

FEBRUARY 14, 2024

The biotech is planning to dissolve less than four years after launching with plans to license drugs and market them in China and other Asian countries.

Licensing 72

Licensing Licensing Marketing Drugs 72

The Pharma Data

APRIL 9, 2021

Biogen enters into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a proposed biosimilar referencing ACTEMRA ® (tocilizumab). Biosimilars have the potential to enable greater access to marketed biologic therapies while generating cost savings and healthcare sustainability. Biogen Inc.

Biosimilars 52

Biosimilars Licensing Licensing Therapies 52

BioPharma Drive: Drug Pricing

AUGUST 1, 2023

Some on Wall Street believe the New York-based biotechnology company is now less likely to get acquired after agreeing to sell partial rights to its only marketed product.

Licensing 52

Licensing Licensing Production Marketing 52

FDA Law Blog: Biosimilars

JUNE 12, 2024

While that’s not to say that OTC hearing aids aren’t working to address the critical issue of hearing loss, it seems that almost two years is still not enough time to assess market impact, or to show that some of the promises of significant savings for large numbers of consumers have been realized.

FDA 111

FDA Regulations Treatment Licensing 111

The Pharma Data

DECEMBER 3, 2020

TWO: 4162) announced today that it has entered into a Collaboration and License Agreement with UK-based Sentinel Oncology Limited for advancing the new drug development of SOL-578 , a Checkpoint Kinase 1 (Chk1) inhibitor, under which PharmaEngine will fund the IND enabling studies for SOL-578. TAIPEI , Dec. About PharmaEngine (TWO: 4162).

Licensing 52

Licensing Licensing DNA Regulations 52

The Pharma Data

JUNE 2, 2022

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.

Licensing 52

Licensing Licensing Therapies Science 52

Perficient: Drug Development

JANUARY 19, 2024

If you want to reduce capital and operational expenditures, speed time to market, and improve scalability, elasticity, security, and compliance, you should consider moving your on-premises IBM Sterling application to IBM supported native SaaS or other cloud solutions which best suits your business.

Compliance 118

Compliance Marketing Licensing Licensing 118

The Pharma Data

MAY 6, 2022

NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have submitted a supplemental Biologics License Application (sBLA) to the U.S. The vaccine is also currently available for individuals 12 through 15 years of age in the European Union under a Conditional Marketing Authorization. . Pfizer Inc.

FDA Approval 52

FDA Approval Licensing Licensing FDA 52

The Pharma Data

AUGUST 19, 2021

today announced that the company’s Marketing Authorization Application (MAA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, has been fully validated and is now under evaluation with the European Medicines Agency (EMA).

Marketing 52

Marketing Treatment FDA FDA Approval 52

The Pharma Data

DECEMBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China. About Burning Rock.

Licensing 52

Licensing Licensing Pharmaceutical Companies Treatment 52

The Pharma Data

MARCH 30, 2021

There can be no guarantee that the FAP targeting agents, including FAPI-46 and FAPI-74, will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time.

Therapies 52

Therapies Licensing Licensing Protein Expression 52

The Pharma Data

DECEMBER 9, 2020

Atlas cofounded, seeded and incubated Vigil, with pre-clinical stage assets in-licensed from Amgen Inc., Vigil’s $50 million Series A financing, completed this week, was powered by Atlas Ventures and Northpond Ventures, and includes participating investors Hatteras Partners and Alexandria Venture Investments. SciNeuro Pharmaceuticals.

Marketing 52

Marketing Small Molecule Disease Pharmaceuticals 52

The Pharma Data

DECEMBER 16, 2020

NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., VICTORIA, British Columbia & ROCKVILLE, Md.–( –( BUSINESS WIRE )– Aurinia Pharmaceuticals Inc.

Licensing 52

Licensing Licensing Pharmaceuticals Disease 52

Drug Target Review

APRIL 23, 2024

The greater use of in silico methods is reflected in the growth of the computer-aided drug design (CADD) market, valued at $3.62 Licensing costs also need to be factored into the cost/benefit analysis, as the licensing terms of some commercial providers can severely limit the number of GPUs that can be used and hence the overall throughput.

Licensing 100

Licensing Licensing Drug Development Drugs 100

Drug Target Review

DECEMBER 9, 2024

Whether directed to a product of an AI or the AI itself, securing a patent is advantageous because it gives the owner exclusive rights to manufacture, use, sell or license their invention for a specified period. Patents can attract investors by assuring intellectual property protection.

Engineering 105

Engineering International Drug Development Science 105

FDA Law Blog: Biosimilars

JANUARY 3, 2024

Palmer & Riëtte van Laack — Most of us love our furry friends, and with the boom in pet ownership during the pandemic, it is no surprise that the market for pet products has become enormous. CVM does not regulate the practice of veterinary medicine (that’s a state licensing board) or vaccines for animal diseases (that’s USDA).

Drugs 59

Drugs FDA Licensing Licensing 59

Agency IQ

JANUARY 4, 2024

Swissmedic reorg adds new focus on medical device market surveillance The Swiss regulator, Swissmedic, just announced a reorganization, with a new head of the medicinal product authorization and vigilance sector, but also a new and discrete medical devices surveillance sector. KAROLINE MATHYS is the head of the new sector.

Marketing 40

Marketing Regulations Clinical Trials International 40

Perficient: Drug Development

OCTOBER 22, 2024

A prominent labor union representing a large number of educators in a major metropolitan public school system recognized this need and partnered with Perficient to implement a scalable Salesforce Marketing Cloud Personalization solution. What is Marketing Cloud Personalization? The team was amazing from start to finish.

Marketing 52

Marketing Nurses Licensing Licensing 52

Perficient: Drug Development

SEPTEMBER 19, 2023

Increased Capabilities for Marketing Cloud and Commerce Cloud Salesforce introduced 26 generative AI capabilities between Marketing Cloud and Commerce Cloud, 14 of which are in GA now, with an additional 14 to arrive by the end of 2024.

Licensing 59

Licensing Licensing Production Marketing 59

Drug Channels

MARCH 15, 2022

Prescription Market (press release) We’re offering special discounted pricing if you order before March 28, 2022. As always, we have updated all market and industry data with the most current information available, including our annual analyses of the market positions of the largest pharmacies, specialty pharmacies, and PBMs.

Pharmacy 83

Pharmacy Specialty Pharmacies Licensing Licensing 83

Drug Channels

OCTOBER 5, 2021

This 2021-22 edition contains the most current financial and industry data along with detailed information about the strategies and market positions of the largest companies: AmerisourceBergen, Cardinal Health, and McKesson. reviews AmerisourceBergen’s entry into the European distribution market. (We Section 4.4. Section 7.4.4.

Pharmaceuticals 61

Pharmaceuticals Biosimilars Licensing Licensing 61

Molecule Blog

AUGUST 6, 2021

An Open Bazaar for Drug Development: Molecule Protocol The complexity of biopharma IP deals When examining the transactional market for biopharma IP, one aspect becomes immediately obvious: IP is not sold in a simple purchase agreement like houses, cars or other physical objects. To achieve this, Molecule chose to use Arweave.

Licensing 52

Licensing Licensing Marketing Research 52

Perficient: Drug Development

NOVEMBER 10, 2023

Depending on the size of the team and anticipated activity within a program, additional RDEs can also be provisioned, however, this may come at an additional licensing cost from Adobe. Where the RDE Resides in a Program and the Deployment Lifecycle The RDE is generally available as an environment on a per-program basis.

Packaging 105

Packaging Licensing Licensing International 105

Perficient: Drug Development

OCTOBER 27, 2023

Spartacus is an open-source JavaScript framework developed by SAP for building modern, responsive, and feature-rich e-commerce storefronts. The Composable Storefront emerged as an ideal solution for expedited market entry. This solution reduces time to market for SAP Commerce new implementations, upgrades, and migrations.

Compliance 105

Compliance Licensing Licensing Marketing 105

FDA Law Blog: Biosimilars

NOVEMBER 1, 2023

FDA recognizes that the FD&C Act exempts licensed healthcare practitioners from certain device regulations if they manufacture devices solely for use in the course of their professional practice. For example, FDA’s regulations have exempted from certain regulatory requirements (e.g.,

Laboratories 81

Laboratories FDA Regulations Licensing 81

Drug Target Review

SEPTEMBER 7, 2023

A patent lawyer by training, Keir represented companies of various sizes in all stages of transactions, including licensing and M&A.

Treatment 98

Treatment Licensing Licensing Disease 98

LifeSciVC

JANUARY 16, 2024

Rise of the best-in-class biologics plays: Are you looking to in-license or invest in “de-risked” biology that is already in the clinic? Gratitude is always in style: Sometimes it takes tough markets and hard conversations to appreciate the positive sentiment and changing tides. Join the club.

Small Molecule 137

Small Molecule Trials Therapies Disease 137

Predictive Oncology

MARCH 17, 2023

Cancer Research Horizons to incorporate PEDAL into future drug discovery processes to enable drug development on a global scale 11 marketed drugs 2nd largest oncology out-licensor globally 150+ active licenses 160+ new drugs into early-phase clinical trials $647 million revenue from royalties & IP $2.8

Research 52

Research Clinical Trials Licensing Licensing 52

DrugBank

AUGUST 15, 2024

Additionally, industry partners bring a wealth of experience in drug development and commercialization strategies, essential for translating scientific discoveries into marketable products that can reach patients worldwide. This highlighted the importance of defining patent scope and licensing terms in such collaborations.

Drug Development 80

Drug Development Clinical Trials Drugs Therapies 80

Drug Channels

FEBRUARY 22, 2022

As always, we have updated all market and industry data with the most current information available, including our annual analyses of the market positions of the largest pharmacies, specialty pharmacies, and PBMs. If you have any questions before purchasing a license to the report, please email me. Click to Enlarge].

Pharmacy 70

Pharmacy Specialty Pharmacies Biosimilars Licensing 70

Drug Channels

FEBRUARY 21, 2023

As always, we have updated all market and industry data with the most current information available, including our annual analyses of the market positions of the largest pharmacies, specialty pharmacies, and PBMs. If you have any questions before purchasing a license to the report, please email me. d/b/a Drug Channels Institute.

Pharmacy 75

Pharmacy Specialty Pharmacies Licensing Licensing 75

FDA Law Blog: Biosimilars

SEPTEMBER 18, 2024

That clause excludes those ingredients that were first marketed as drug ingredients. MKP) asserting that “NMN is excluded from the dietary supplement definition under [FDC Act § 201(ff)(3)(B)(ii)] and may not be marketed as or in a dietary supplement.”

Production 59

Production FDA Licensing Licensing 59